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Fingolimod (FTY720) is an orally bio-available immunomodulatory drug currently 
approved by the FDA for the treatment of multiple sclerosis. Currently, there is a signif-
icant interest in the potential benefits of FTY720 on stroke outcomes. FTY720 and the 
sphingolipid signaling pathway it modulates has a ubiquitous presence in the central 
nervous system and both rodent models and pilot clinical trials seem to indicate that the 
drug may improve overall functional recovery in different stroke subtypes. Although the 
precise mechanisms behind these beneficial effects are yet unclear, there is evidence 
that FTY720 has a role in regulating cerebrovascular responses, blood–brain barrier 
permeability, and cell survival in the event of cerebrovascular insult. In this article, we 
critically review the data obtained from the latest laboratory findings and clinical trials 
involving both ischemic and hemorrhagic stroke, and attempt to form a cohesive picture 
of FTY720’s mechanisms of action in stroke.
Keywords: stroke, neuroprotection, vascular endothelium, fingolimod, Fty720, hemorrhagic stroke, sphingosine-
1-phosphate
introdUCtion
Fingolimod (FTY720) is an orally bio-available immunomodulatory drug unique for its reversible 
leukocyte sequestration properties. In 2010, it was approved by the FDA for the treatment of multiple 
sclerosis (MS) (1, 2).
Given the current understanding of the role of the immune system in the pathophysiology of 
brain injury in cerebrovascular diseases, there is now significant interest in the potential benefits 
of FTY720 on stroke outcomes. Several groups have independently evaluated its effects in rodent 
models of brain ischemia and intracerebral hemorrhage (ICH). More recently, pilot clinical trials 
have been conducted demonstrating promising results, albeit in small populations (3–5). Taken 
together, these studies seem to indicate that administration of FTY720 results in overall improved 
functional recovery in different stroke subtypes.
The precise mechanisms behind these beneficial effects are still under investigation. FTY720 is 
a partial sphingosine-1-phosphate (S1P) agonist with immunomodulatory properties that regulates 
cerebrovascular responses, blood–brain barrier (BBB) permeability, and central nervous system 
(CNS) cell survival (6, 7). In this article, we will organize these elements and attempt to form a 
cohesive picture of FTY720’s mechanisms of action in stroke, and critically review the data obtained 
from recent clinical trials.
taBLe 1 | distribution and function of s1p receptors in the Cns (28, 29).
Cell type type of receptor Function
Neuron S1P1 = S1P3 > S1P2 = S1P5 Neurogenesis, neural 
progenitor migration, 
cell survival, and 
neurotransmission
Oligodendrocyte S1P5 > S1P1 = S1P2 > S1P3 Oligodendrocyte 
precursor cell survival, 
migration, differentiation, 
and morphology
Astrocyte S1P3 > S1P1 > S1P2 > S1P5 Proliferation, migration, 
gap function 
communication, and 
growth factor production
Microglia S1P1 > S1P2 > S1P3 = S1P5 Pro-inflammatory 
cytokine production
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roLe oF tHe iMMUne systeM in 
stroKe proGression
Immunomodulation is a well-characterized effect of FTY720 and 
is thought to mediate some of the beneficial effects seen in stroke 
models. In order to understand the extent to which the immune 
system impacts the evolution of stroke outcomes, we will sketch 
a proposed model of the immune cascade following ischemic 
insult.
In the immediate aftermath of an ischemic event, comple-
ment activation, clot formation, and oxidative stress result in 
direct damage to local vasculature. Endothelial cells die and 
detach, interrupting the integrity of the BBB and exposing 
sub-endothelial antigens. Immune cells adhere to the vessel wall 
and upregulate the expression of chemoattractant and adhesion 
molecules that lead to the infiltration of the brain parenchyma by 
the innate immune system.
A combination of neutrophils, monocytes, and macrophages, 
this innate immune system further contributes to vascular com-
promise and early inflammation. One well-documented process 
is through the release of matrix metalloproteinases (MMPs) by 
the immune cells, particularly MMP-9, which contributes to the 
breakdown of the BBB with the resultant edema and growth of 
the infarcted area (8).
In the parenchyma, glial cells are also activated by the inflam-
mation and damage-associated molecular patterns (DAMPs) 
released from dying neurons. These reactive astrocytes and 
microglia further stimulate the recruitment of leukocytes, which 
release their own pro-inflammatory chemokines, perpetuating a 
cycle of vascular damage, inflammation, and cell death (9).
The second, adaptive phase of the immune response is medi-
ated predominantly by effector T cells, which are stimulated by 
DAMPS and brain-specific antigens released upon neuronal 
cell death (10). These T cells mobilize to the injured regions 
of the brain, infiltrating a compromised BBB to release pro-
inflammatory cytokines, including IFN-γ, resulting in a delayed 
neurotoxic effect (11, 12). Of note, brain-specific antigens were 
identified in cervical nodes and palatine tonsils of animals with 
cerebral ischemia and stroke survivors. Interestingly, some of 
these antigens were associated with infarct volume and survival. 
While these studies need to be replicated in larger cohorts, they 
suggest the participation of peripheral lymphoid tissue in stroke-
associated inflammation and outcomes.
Lastly, the inflammatory process is brought to an end via 
a combination of B cells and regulatory T cells. The latter acts 
through IL-10, which in combination with TGF-β produced by 
local macrophages, suppresses further helper T-cell-induced 
inflammation, and promotes the regeneration of remaining viable 
neurons (13, 14).
A reduction in various components of the innate and adap-
tive immune response have been associated with better stroke 
outcomes. Clinically, a lower ratio of CD14+ pro-inflammatory 
monocytes to CD16+ reparative monocytes has been correlated 
with better acute and long-term functional outcomes (15). 
Similarly, decreased complement activation, specifically the 
reduced expression of C3, C4, and C-reactive protein, has been 
associated with better recovery at 3  months post-stroke (16). 
Experimentally, inhibition of CD8+ and CD4+ T-cell migration 
into the CNS and direct disruption of CD8+ cytotoxicity has 
led to reduced infarct volume and post-ischemic inflammation 
(17). Disruption of the DAMPs-activated γδT cells have also 
resulted in decreased infarct size and better functional recovery 
in mice (18). Finally, direct delivery of B cells and IL-10 to the 
brain in animal models have resulted in a reduction of inflam-
matory cytokines produced by effector T cells and a reduction 
of infarct size (19, 20).
FinGoLiMod and stroKe-reLated 
MeCHanisMs oF aCtion
pharmacology
Isaria sinclairii, otherwise known as “winter-insect and summer-
plant,” is a fungus that has been used in traditional Chinese medi-
cine for over 300 years. Classically prescribed as a panacea for 
multiple ailments, it produces an atypical amino acid myriocin 
(ISP-1) that blocks the synthesis of sphingolipids. This chemi-
cal compound has since been modified into fingolimod, also 
known as FTY720 (21). In Western Medicine, FTY720 initially 
showed promise in preventing ischemic–reperfusion injury 
following organ transplant, but failed clinical trials due to the 
development of acute macular edema in some patients (22, 23). 
In 2010, it became the first oral disease modifying drug approved 
for treatment of MS (6). In its base form, FTY720 is an orally 
bio-available, lipophilic molecule that readily crosses the BBB 
and steadily accumulates in the CNS white and gray matter (24). 
It bears a structural similarity to sphingosine and is reversibly 
phosphorylated primarily by Sphingosine-Kinase 2 (SphK2) and, 
to a lesser extent, by SphK1 (25). In its activated form, FTY720-
phosphate is a sphingosine-1-phosphate (S1P) analog that binds 
to cell membrane G-coupled S1P receptors (S1PR) S1PR1, 3, 4, 
and 5, but not S1P2 (26). With the exception of S1PR4, these 
receptors are ubiquitously distributed in the CNS (Table 1). In 
addition to its action on cell surface receptors, FTY720 regulates 
the synthesis of different bioactive sphingolipids and, together 
with S1P, regulates gene expression via epigenetic mechanisms 
(Figure  1). The half-life of FTY720 averages ~9  days and its 
FiGUre 1 | overview of sphingosine-1-phosphate (s1p) and fingolimod (Fty720) effects. S1P signals through five different G protein-coupled cell surface 
receptors (S1PR 1-5). S1PR1–3 are ubiquitously expressed throughout the body. In comparison, S1PR4 is predominantly expressed in the immune system and 
S1PR5 in the central nervous system (CNS) and the spleen. These receptors are associated with different profiles of Gα subunits, including Gi, Gq, and G12/13. The 
profile of S1PR and Gα subunit expression enable cells to activate different downstream signaling pathways and to orchestrate complex responses in response to 
single agonist. The activated form of FTY720, FTY720-phosphate (FTY720-P), is a partial agonist of all the S1PRs, with the exception of S1PR2. Downstream, 
S1PRs regulate oxidative-stress-induced cell survival, endothelial barrier function, leukocyte migration and taxis, and oligodendrocyte survival and proliferation in the 
CNS (26, 30, 31). In the presence of FTY720-P, S1PR1 is downregulated from the cell surface impeding the egress of lymphocytes from lymph organs and causing 
lymphopenia (32). S1P and FTY720-P also regulate gene transcription through non-receptor-related epigenetic mechanisms related to the inhibition of histone 
deacetylases (HDAC). Insert: metabolism of sphingolipids (33). Ceramide, a central hub in the metabolism of sphingolipids, has been associated with cell death, 
quiescence, and differentiation. It can be generated by the breakdown of sphingomyelin by the acid or neutral sphingomyelinases, or synthesized de novo from 
serine and palmitoyl-CoA by serine-palmitoyl transferase and ceramide synthase. Ceramide can be metabolized into sphingosine which is then phosphorylated into 
S1P by the sphingosine-kinase 1 (SphK1) or 2 (SphK2). S1P is broken down into hexadecenal and phosphoethanolamine by the S1P-lyase. FTY720 is 
phosphorylated primarily by SphK2. Both S1P and FTY720-P are transported to the extracellular space by the membrane transporter Spns2 (34). In addition to its 
effect on cell membrane receptors and HDAC, FTY720 also inhibits several key enzymes involved in the metabolism of sphingolipids, including ceramide synthase, 
acid sphingomyelinase, and S1P-lyase. AC, adenylate cyclase; ERK, extracellular signal-regulated kinase; PKB, protein kinase B; PLC, phospholipase C.
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pharmacology is not sensibly affected by age, weight, sex, or 
ethnicity (27).
immunomodulation
Immunomodulation, particularly peripheral lymphocyte seques-
tration, is a well-documented mechanism of FTY720. S1P1-
receptors are expressed on CCR-7 positive lymphocytes and play 
a key role in inflammation, stimulating lymphocyte release from 
peripheral lymphoid tissues in response to endogenous S1P gra-
dients (35, 36). Lymphocyte S1P1-receptor binding by FTY720 
results in a functional antagonism via involution and degradation 
of this cell surface receptor, ultimately inhibiting lymphocyte 
recirculation (37). In rodent models using 1 mg/kg of FTY720 at 
1-, 24-, and 48-h intervals, 60% peripheral lymphopenia can be 
FiGUre 2 | effect of fingolimod (Fty720) on cerebral ischemia/reperfusion-associated astrogliosis. Male adult Sprague-Dawley rats were subjected to 
middle cerebral artery occlusion (MCAo) for 60 min followed by reperfusion as previously described (45). Three hours after reperfusion, animals were treated with 
vehicle or 0.5 mg/kg FTY720 intraperitoneally. Brains were harvested at 48 h after surgery, fixed in paraformaldehyde, and mounted to slides. Immunofluorescence 
staining was performed using anti-glial fibrillary acidic protein antibody (astrocytes; green), anti-endothelial barrier antigen antibody (endothelial cells; red), and DAPI 
(nuclei; blue) (bar: 200 μm). Representative images obtained for sham, MCAo-vehicle control, and MCAo-FTY720 animals (n = 5 per group). A marked increase in 
astrogliosis was observed in the MCAo-vehicle group, and this was markedly ameliorated in MCAo-FTY720-treated animals.
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achieved within 6 h of first administration with peak suppression 
lasting for 7–9 days (38). By reducing the quantity of infiltrating 
lymphocytes, FTY720 effectively decreases the direct neurotoxic 
effects of the adaptive immune system upon the CNS and reduces 
secondary ischemic damage caused by cytokine-induced inflam-
mation of the surrounding microvasculature (39–41).
Fingolimod may also attenuate the neuroinflammatory 
response by acting directly on reactive glial cells, which are 
activated within minutes following ischemic injury (42). Studies 
done in rodent models of cerebral ischemia show that FTY720 
ameliorates the influx of leukocytes in the ischemic brain and 
reduces the expression of pro-inflammatory cytokines (IL-1β 
and IFN-γ) and adhesion molecules, such as intercellular 
adhesion molecule-1 (ICAM-1) (38, 41). Studies done in  vivo 
in our own laboratory confirm that FTY720 reduces leukocyte 
adhesion to pial vessels and ameliorates astrogliosis in cerebral 
ischemia–reperfusion models (Figures 2 and 3). In non-stroke 
models, FTY720 both suppressed TNF-α-induced inflammatory 
genes and stimulated the production of neurotrophic mediators 
via S1P1 and S1P3 receptors on astrocytes (43). In particular, 
FTY720 decreased ceramide production, a pro-inflammatory 
lipid that causes loss of BBB integrity and increased infiltration 
of immune cells into the CNS (44). In support of FTY720’s direct 
CNS effects, direct infusion of FTY720 into rat brains in MS mod-
els has been shown to decrease disease severity in the absence of 
peripheral lymphopenia (7).
Vasoprotection
It is possible that FTY720 also provides a vasoprotective effect in 
a manner related to its immunomodulatory action. There is some 
evidence that FTY720 can induce granulocyte and macrophage 
colony-stimulating factor (GM-CSF) release from astrocytes, 
which may limit endothelial cell death after exposure to TNF-α 
and IFN-γ (47). The presence of astrocyte-derived GM-CSF 
also suppresses ICAM-1 expression in endothelial cells (48). 
Decreased surface ICAM-1 reduces leukocyte adhesion to the 
vessel walls and local platelet activation, which leads to reduced 
thrombosis and associated inflammation, improving microvas-
cular function (39, 49).
Furthermore, S1P1-receptors are expressed on endothelial 
cells and administration of FTY720 may directly enhance BBB 
integrity. First, FTY720 has been shown to directly decrease 
endothelial ICAM-1 expression in stroke models, which may 
further contribute to ameliorating the no-reflow phenomenon 
(41). Second, in non-stroke-related models, FTY720 can stimu-
late endothelial cells to recruit proteins for adherence junction 
assembly, reducing vascular permeability and neutrophil infiltra-
tion (50). Finally, there is evidence that administration of FTY720 
blocks VEGF-induced permeability in human umbilical vein 
endothelial cells and regulates endothelial cell barrier capacity 
and vascular permeability in lungs (51). A similar process may 
also help to maintain the structural integrity of the BBB.
Taken together, these immunomodulative and vasoprotective 
mechanisms may contribute to FTY720’s ability to decrease 
secondary edema formation following cerebral ischemia (41). 
Such a process would also be consistent with our rat model of 
middle cerebral artery (MCA) ischemia–reperfusion, where 
FTY720 treatment resulted in decreased ipsilateral brain edema 
compared to the vehicle group (Figure 4). Vasoprotection may 
also account for reduction in hemorrhagic transformation 
after delayed recombinant tissue plasminogen activator (tPA or 
alteplase) administration (at 3 h post-stroke), at least in moderate 
sized thromboembolic strokes (52, 53).
direct neuroprotection
In addition to glial cells, S1P-receptors are ubiquitous within the 
CNS, with multiple receptor subtypes present on neurons and 
oligodendrocytes (28). Experimental evidence has shown that 
fingolimod has direct effects on astrocytes, microglia, oligoden-
drocytes, neurons, and BBB endothelial cells, which are all affected 
after stroke (Table 2) (7). There is also increasing evidence that 
FTY720 may achieve some of its protective effects by directly 
interacting with neuronal S1P1 and S1P3 receptors, promoting 
production of anti-apoptotic factors and increasing resilience 
against ischemic injury. One proposed mechanism of direct 
neuroprotection is via the S1P/Phosphatidylinositol-3-Kinase 
(PI3K)/Akt/FOXO3a axis. Administration of FTY720 results 
in phosphorylation of Akt, which in turn prevents activation of 
FOXO3a, a transcription factor critical in mediating oxidative 
stress-induced cell death. In ischemic conditions, this suppression 
of FOXO3a by FTY720 may contribute to continued neuronal 
survival (54). FTY720 may also provide a neuroprotective effect 
FiGUre 3 | assessment of neuroinflammation after cerebral ischemia reperfusion. Male adult Sprague-Dawley rats were subjected to middle cerebral artery 
occlusion (MCAo) for 60 min followed by reperfusion. Three hours after reperfusion, animals were treated with vehicle or 0.5 mg/kg FTY720 intraperitoneally. 
Leukocyte adhesion to pial venules was determined 24 h after reperfusion by intravital microscopy using rhodamine 6G-labeled autologous leukocyte as previously 
described (46). (a) Representative pictures of the vessel anatomy and the trafficking of leukocytes 1 and 2 h after leukocyte labeling with Ro6G in sham, vehicle 
control, and FTY720-treated animals. (B) Quantification of leukocyte adhesion, expressed as the percentage of the vessel area occupied by adherent leukocytes 
measured 1 h after leukocyte labeling. The MCAo-vehicle group demonstrated a significant increase in vascular leukocyte adhesion at 24 h post reperfusion 
compared to sham. The treatment with FTY720 decreased the adherence of leukocytes to pial vessels by almost 60%. Significance determined using an unpaired 
t-test. Means ± SD (n = 5).
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through the ERK/bcl-2 pathway. Administration of FTY720 
results in persistent ERK phosphorylation in the face of ischemic 
insult, resulting in enhanced levels of the anti-apoptotic protein 
Bcl-2, thus rescuing neurons from apoptosis (55).
Pretreatment with FTY720 at 48  h before MCA ischemia–
reperfusion also leads to an ischemia tolerant phenotype in 
mice models mimicking the effect of hypoxic preconditioning 
and decreasing subsequent brain ischemia volume by 33%. 
This mechanism is hypothesized to act via a hypoxia-inducible 
factor (HIF), SphK2/S1P1-receptor, and chemokine (C–C 
motif) ligand-2 (CCL2) signaling pathway, ultimately result-
ing in increased CCL2 expression in neurons (57). CCL2 is a 
leukocyte-derived pro-inflammatory chemokine shown to be 
protective against ischemia in the myocardium (58). It is possible 
that prophylactic treatment with FTY720 leads to early exposure 
to low doses of CCL2, which may prime neurons against future 
ischemic damage, however, the exact mechanism remains to be 
fully elucidated (59).
FiGUre 4 | infarct volume and brain edema in rats subjected to cerebral ischemia reperfusion. Male adult Sprague-Dawley rats were subjected to middle 
cerebral artery occlusion (MCAo) for 60 min followed by reperfusion. Three hours after reperfusion, animals were treated with vehicle or 0.5 mg/kg FTY720 
intraperitoneally. Infarct volume was determined as previously described (56). Brain edema was determined by measuring hemispheric water content (41).  
(a) Representative coronal brain cuts obtained 24 h after MCAo. The arrows highlight areas of cerebral infarction. Brain cuts were digitalized and infarct volume 
determined by using the image analysis software (MetaMorph; Universal Imaging Corp., Downingtown, PA, USA). (B) Brain edema determined in the ipsilateral and 
contralateral hemisphere. Compared to vehicle animals, the treatment with 0.5 mg/kg FTY720 reduced infarct volume and brain edema. Significance determined 
using an unpaired t-test. Means ± SD (n = 5).
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taBLe 2 | Central nervous system effect of fingolimod (7).
Cell type Function
Neuron Protects from excitotoxic death
Restores neuronal function
Oligodendrocyte Increases survival of oligodendrocyte precursor cells
Enhances remyelination
Regulates migration, differentiation, and process dynamics
Astrocyte Inhibits pro-inflammatory cytokine production
Inhibits astrogliosis
Regulates cell migration
Microglia Reduces microglial activation
Ameliorates microgliosis
Blood–brain barrier Reduces blood–brain barrier leakiness
7
Li et al. FTY720 in Stroke
Frontiers in Neurology | www.frontiersin.org August 2016 | Volume 7 | Article 139
Finally, S1P and FTY720 have intracellular effects that are not 
mediated by cell surface receptors (60). One identified mechanism 
is the epigenetic regulation of histone acetylation. Both agents 
are class I histone deacetylase (HDAC) inhibitors and elevated 
levels of intranuclear S1P or phosphorylated-FTY720 increase 
acetylated histone H3 (61). This epigenetic phenomenon has been 
associated with alterations in hippocampal neurons and rescuing 
memory deficits independent of FTY720’s immunosuppressive 
actions (62). The beneficial effect of fingolimod on cognition has 
also been shown in experimental models of neurodegeneration 
and neuroinflammation, and in memory performance after 
cerebral ischemia–reperfusion (63–66). However, whether this 
effect is related to epigenetic mechanisms is yet to be determined.
FinGoLiMod in CLiniCaL triaLs
Given the consistent benefits demonstrated in laboratory stroke 
models and the favorable safety profile observed in clinical trials 
involving MS patients (67), some research groups have started to 
assess FTY720 in stroke subjects. So far, the results of three small-
sized studies have been published by the Tianjin Neurological 
Institute looking at patients with anterior circulation acute 
ischemic strokes (AIS) and ICH (3–5).
ischemic stroke
Two small clinical trials investigated the effect of FTY720 in acute 
cerebral ischemia. The first study published in 2014 was an open-
label, evaluator-blinded, non-randomized study that examined 
the effect of FTY720 on ischemic stroke compared to standard 
of care alone. The inclusion criteria included age >18  years, 
National Institute of Health Stroke Score (NIHSS) score at base-
line ≥5, anterior circulation ischemic stroke, and time of onset 
to admission within 4.5–72 h. Major exclusion criteria included 
history of bradyarrhythmia or atrioventricular blocks, use of anti-
neoplastic or immunomodulating therapies, and macular edema. 
A total of three consecutive oral doses of FTY720 0.5 mg daily 
were administered to the study group. The first dose of the study 
drug was given 1 h after the baseline MRI and no later than 72 h 
after symptoms onset. The primary endpoint was lesion size at 
7 days and microvascular permeability and clinical improvement. 
Clinical outcomes included (a) NIHSS which is a stroke severity 
score that ranges from 0 to 42, with higher numbers representing 
increased stroke severity; (b) modified Barthel index (mBI) which 
is a validated score of dependency; this score runs from 0 to 100 
with higher numbers denoting better outcome with increasing 
independency to perform activities of daily living; and (c) modi-
fied Rankin Scale (mRS) which is a tool that assesses disability; 
this scale ranges from 0 to 6, with 0 denoting perfect health and 
6 death.
A total of 22 patients were assigned to the control or the 
FTY720 groups. The treatment with fingolimod was initiated at 
an average of 20 h after stroke onset. Both the control (n = 11) and 
the study groups (n = 11) had comparable baseline characteristics. 
Compared to the lesion volume and location-matched control 
group, there was no significant decrease in lesion size at 7 days 
on FLAIR imaging (70 ± 26 vs. 85 ± 30 ml, P = 0.69). However, 
lesion expansion was more commonly seen in the controls (9 ± 3 
vs. 27 ± 8 ml, P = 0.0494) and infarct volume extension ratio, 
defined as the ratio of infarct volume change from baseline to day 
7/infarct volume at baseline, was significantly decreased in the 
FTY720 group (15.2 ± 4.2 vs. 41.6 ± 4.5, P = 0.0003). In addition, 
microvascular permeability, measured as parenchymal enhance-
ment contrast-enhanced T1-weighted imaging, was 2× higher 
in controls compared to the FTY720-treated group (p = 0.005). 
In terms of functional outcomes, study patients demonstrated 
significant improvement in neurological functions within the 
first week. This was again observed at 90 days post stroke, with 
significantly lower NIHSS scores (1.7 ± 0.8 vs. 5.8 ± 1.7, P = 0.02) 
and significantly higher mBI (62 ± 11 vs. 87 ± 8, P = 0.0049). 
In addition, decreased neurological disability, defined as a mRS 
score of 0–1 at 90 days, was more commonly seen in the FTY720 
groups than in controls (0 vs. 73%; P = 0.009). In terms of safety, 
the treatment with FTY720 resulted in a sustained lymphopenia 
that persisted for more than 7  days and resolved by day 30. 
Significantly, the rate of complications and adverse reactions, 
including bradycardia, macular edema, or infections, were simi-
lar in the control and the study groups.
In 2015, a second randomized, open-label, evaluator-blinded 
study was conducted to assess the efficacy of FTY720 in conjunc-
tion with tPA. The inclusion criteria included age 18–80 years, 
first-ever hemispheric stroke due to anterior or middle cerebral 
artery occlusion (MCAo), and initial NIHSS score ≥5. Patients 
were excluded from the study if they had contraindications 
to tPA, pre-existing disability, history of bradyarrhythmia or 
atrioventricular blocks, concurrent use with antineoplastic or 
immunomodulating therapies, and macular edema. The first dose 
of fingolimod was given before alteplase administration. Similar 
to the previous study, a total of three doses of 0.5 mg oral fingoli-
mod were given in consecutive days. Lesion size, hemorrhagic 
volume, and NIHSS scores at 24 h were the primary endpoints; 
also assessed were lesion size at day 7 and clinical improvement 
up to day 90.
A total of 47 patients were randomly assigned to receive tPA 
alone or tPA plus FTY720. The mean time from stroke onset to 
initiation of treatment was ~3  h. The baseline characteristics 
of the control and the study groups were comparable with the 
exception of atrial fibrillation that was more commonly seen 
in the FTY720 group. Recanalization rates were the same in 
both groups, but compared to the control group, the combined 
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treatment with FTY720 and alteplase resulted in decreased 
infarct volume expansion (10.1 ± 1.2 vs. 34.3 ± 10.4 ml; P = 0.04), 
decreased hemorrhagic transformation volume (1.2  ±  0.4 vs. 
4.4 ± 1.1 ml; P = 0.01), lower rate of parenchymal hemorrhage 
(0 vs. 36%; P =  0.002), and greater improvements in NIHSS 
scores (4 vs. 2; P = 0.02), all at 24 h. At day 7, the combination 
therapy also demonstrated decreased lesion volume compared to 
alteplase treatment alone (−2.3 ± 2.7 vs. 12.1 ± 3.7 ml; P < 0.01) 
and greater improvement in the NIHSS score from the presenting 
stroke (2.5 vs. 1; P < 0.01). At 3 months, the rate of patients with 
good neurological outcome, defined as mRS 0–1, was higher in 
the group of patients that received FTY720 plus tPA (73 vs. 32%; 
P = 0.01). From the safety stand point, malignant cerebral edema 
requiring craniotomy occurred in only one patient receiving tPA 
monotherapy but in none of the subjects in the tPA plus alteplase 
group. Aside from the expected lymphopenia resulting from the 
use of FTY720, safety outcomes were comparable in both groups.
During ischemia, lymphocytes interact with endothelial cells 
and platelets to induce microvascular dysfunction and enhanced 
thrombosis. This process, referred to as no reflow, occurs within 
a few hours after the ictus and results in the obliteration of small 
capillaries. In addition, the occurrence of ischemia is associated 
with a profound local inflammatory response. The term throm-
boinflammation refers to the active interplay that occurs between 
thrombotic and inflammatory mechanisms. Data obtained in 
experimental models of cerebral ischemia/reperfusion demon-
strate that FTY720 ameliorates the number of lymphocytes in the 
intracranial vascular compartment and reduces ischemia-associ-
ated vascular dysfunction and microvascular thrombosis. Thus, 
it is conceivable that FTY720 contributes to improved outcome 
in cerebral ischemia by reducing thromboinflammation (39). In 
addition, enhanced inflammation has been linked to BBB dysfunc-
tion and increased risk of hemorrhagic transformation. Studies 
done in animal models of MCA thromboembolic occlusion show 
that FTY720 attenuates BBB dysfunction and hemorrhagic trans-
formation with delayed tPA administration at 3 h post-stroke (53).
intracerebral Hemorrhage
Intracerebral hemorrhage constitutes a neurological emergency 
that carries a mortality of ~50%. Hematoma volume and location, 
age, and the presence of intraventricular extension are established 
predictors of outcome. Perihematomal edema occurs within 
the first 72 h post ictus and contributes to both morbidity and 
mortality (68). The breakdown of the hematoma attracts immune 
cells that infiltrate the parenchyma and secrete pro-inflammatory 
cytokines and MMPs. These mediators disrupt the BBB and 
facilitate the recruitment of additional leukocytes that results in a 
vicious cycle that contributes to secondary brain injury. Peripheral 
immune cells, including T-lymphocytes, have been identified 
as active contributors to perihematomal edema. Studies done 
in experimental models show that the treatment with FTY720 
ameliorates ICH-associated infiltration of lymphocytes and the 
expression of adhesion molecules and other cytokines, includ-
ing intercellular adhesion molecule-1 (ICAM-  1), interferon-γ 
(INF- γ), and interleukin-17 (IL-17) at 72 h after ICH. This reduc-
tion in neuroinflammation was associated with reduced cerebral 
edema, neuronal apoptosis, and brain atrophy and improved 
neurological outcome (69–71). These findings supported the 
notion that fingolimod may be protective in ICH.
The Tianjin group investigated the use of FTY720 in non-trau-
matic ICH using an open-label evaluator-blinded case-control 
study. The inclusion criteria included supratentorial cerebral 
hemorrhages between 5 and 30  ml, Glasgow Coma Scales >6, 
and symptom onset within 72 h prior to admission. Patient were 
excluded from the study if they had dysphagia, nausea or vomit-
ing, hematoma expansion, pre-existing disability (defined as 
mRS > 1), bradycardia or atrioventricular block, secondary ICH, 
macular edema, or concomitant use of antineoplastic or immu-
nomodulatory treatment. Patient were matched by NIHSS as well 
as hematoma volume and location and then randomly assigned 
to the FTY720 or control groups. Primary endpoints included 
perihematomal edema volume at 7 and 14 days (defined by MR 
imaging), and functional recovery at 90 days. Clinical manage-
ment was left to the discretion of the treating physician. A total of 
23 subjects met the inclusion and exclusion criteria, 11 of whom 
received 0.5  mg of FTY720 orally daily for three consecutive 
days. Mean time from stroke onset to intervention was 20 h, with 
FTY720 administered roughly 1 h after initial CT evaluation.
Both the control and the FTY720 groups had similar baseline 
characteristics, with the exception of a higher representation of 
females in the FTY720 arm. The circulating levels of CD4+ T cells, 
CD8+ T cells, and CD19+ B cells dropped abruptly after the third 
dose of FTY720. The initial hematoma volume in both groups was 
comparable (15.4 vs. 16.7 ml, P = 0.68). At 7 days post ictus, the 
perihematomal edema volume in the FTY720-treated group was 
significantly lower than that in the control group (47 vs. 108 ml, 
P =  0.04). At 14  days, the FTY720 group continued to have a 
smaller perihematomal edema volume than the control group but 
this was not statistically significant (55 vs. 124 ml, P = 0.07). The 
loss of significance at 14  days post ICH may represent a floor 
effect or lack of power. However, it is important to highlight that 
100% of FTY720 patients had a striking functional recovery with 
a GCS of 15 by day 7 compared to 50% of the controls. The rate 
of patients with good clinical outcome, defined as an mRS of 0 
or 1, was 63% in the FTY720 group and 0% in the control group 
(P = 0.001). In addition, 63% of the subjects treated with FTY720 
had reduced dependency after ICH, defined by an mBI score of 
95–100, as compared to 0% in the control group. In terms of safety 
outcomes, a single case of transient asymptomatic bradycardia 
was reported in the group treated with FTY720. Otherwise, both 
groups had no major differences in the frequency of infections or 
cardiac arrhythmias.
It is plausible that the reduction in perihematomal edema 
observed in ICH patients treated with FTY720 relates to its 
immunomodulatory effects. However, other mechanisms may 
contribute to this phenomenon. By inducing cytoskeletal rear-
rangement and increasing the expression of adhesion molecules, 
including VE-cadherin and β-catenin, S1P has been shown to 
enhance endothelial barrier permeability and leukocyte entry 
(50). In addition, the participation of S1P-signaling pathways 
in endothelial integrity and BBB function has been described in 
different scenarios. In the rodent model of experimental autoim-
mune encephalomyelitis, for example, treatment with fingolimod 
modified the expression of MMPs resulting in a proteolytic 
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balance favoring BBB integrity; and in experimental cerebral 
malaria, treatment increased serum levels of angiopoietin-1, a 
marker of endothelium quiescence and stability (72, 73). In addi-
tion, FTY720 was shown to block VEGF-induced permeability in 
human umbilical vein endothelial cells and to regulate endothelial 
cell barrier capacity and vascular permeability in lungs (51, 52). 
Whether these mechanisms contributed to the improved out-
come observed in ICH patients treated with FTY720 is still to be 
determined.
disCUssion
Of the small-scale pilot studies described above, larger sample 
sizes in the setting of double-blinded, fully randomized design 
would be the next step in validating the results. Better gender 
balance, racial diversity, as well as homogeneity in lesion location, 
and neurologic deficit are also worth consideration. Compared to 
laboratory studies, clinical trials have not shown significant reduc-
tions in primary infarct size. Differences in modes of delivery and 
dosing regimens beyond the 3 days may help assess the ability of 
FTY720 to achieve reductions in primary lesion size in humans. 
A larger phase 2 study looking the efficacy and safety of FTY720 
in AIS is currently underway. We anticipate that the results of this 
trial will provide additional valuable data to determine the role of 
fingolimod in the treatment of this condition (74).
Regarding the concern of suppressing an already compro-
mised immune system during the subacute stage of stroke, stroke 
induced immunodepression is a well-characterized phenomenon 
thought to contribute to the high prevalence and morbidity of 
common infections during ICU and hospital stay (10, 13). So far, 
however, no significant increase in spontaneous bacterial infec-
tions has been reported in either laboratory studies or clinical 
trials (75).
Finally, in the laboratory studies described above, some 
contradictory data have not been fully accounted for. Wei et al. 
were unable to reduce glutamate or hydrogen peroxide-induced 
cytotoxicity through administration of FTY720 or S1P, which 
could argue against the direct neuroprotective effects of FTY720 
(41). Also, CCL2, which is elevated in neurons by pretreatment 
with FTY720 and implicated in the development of an ischemia 
tolerant phenotype in stroke models, is shown to be deleterious 
when expressed by reactive astrocytes in MS models (76). These 
and other discrepancies, which will require future verification, 
may prove to be critical in fully understanding FTY720 and S1P’s 
mechanism in stroke-related injuries.
ConCLUsion
We are just now beginning to understand the role that FTY720 
plays in stroke recovery. Taken together, current laboratory and 
clinical data suggest a beneficial role of FTY720 in preventing 
secondary progression of tissue injury and promoting short- and 
long-term rehabilitation, both in AIS with and without tPA, and 
in ICH. There is also growing evidence supporting the protective 
effect of fingolimod in subarachnoid hemorrhage (77). Although 
the exact mechanism is still elusive, that these results are at least 
in part due to the peripheral sequestration of lymphocytes has 
been largely accepted. Evidence also exists for other forms of 
immunomodulation through attenuating reactive astrocytes, 
vasoprotection (both immune-related and direct), and direct 
neuroprotection through surface and intracellular S1P receptors.
The sphingolipid signaling pathway modulated by fingolimod 
have a ubiquitous presence in the CNS, affecting various disease 
states from Parkinsonism to epilepsy and brain tumors (6, 78). 
The data presented in this review are predominantly gathered 
from stroke-related research but includes MS models as well. It is 
likely that as progress is made in uncovering FTY720 and S1P’s 
role in other diseases, mechanisms pertaining to stroke will also 
come to light. In the meantime, we appear to have a drug that 
continues to show promise in ameliorating the effects of stroke 
and one that may change the future prognosis and management 
of cerebrovascular diseases.
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